Heron Therapeutics (HRTX) PT Lowered to $13 at Cowen

Cowen analyst Boris Peaker lowered the price target on Heron Therapeutics (NASDAQ: HRTX) to $13.00 (from $31.00) while maintaining an Outperform rating following disappointing Q4 results.

The analyst commented, "Heron reported disappointing 4Q21 earnings with Zynrelef reaching sales of only $0.8MM (-61% Q/Q). We anticipate a slower growth rate than originally expected for Zynrelef sales. HTX-019 is on track for launch in 4Q22 with a PDUFA date set on September 17, 2022. Heron has cash sufficient into 3Q22 and will likely need to raise capital prior to this. Reducing price target to $13.00."

You May Also Be Interested In

• St. James's Place plc (STJ:LN) (STJPF) PT Raised to GBP20.50 at Deutsche Bank
• Axis Capital Limited Upgrades Tata Technologies (TATATECH:IN) to Buy (1)
• RBC Capital Starts PRO REIT (PRV-U:CN) at Outperform